Dual Microparticle System for Antigen-Specific Tolerance in Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell-based vaccines for autoimmune diseases like multiple sclerosis are limited by ex-vivo manipulation requirements, high costs, and inefficiencies in antigen presentation and immune cell targeting, leading to significant side effects and limited therapeutic options for autoimmune disorders.
Innovation Solution
Development of antigen-specific, dual-sized polymeric microparticle systems that deliver specific antigens and tolerogenic factors to recruit and modulate dendritic cells, inducing a tolerogenic phenotype without systemic immunosuppression, using phagocytosable and non-phagocytosable microparticles loaded with immunomodulatory agents like IL-10, TGF-β, and GM-CSF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ex-vivo manipulation of patients' dendritic cells is used, then antigen-specific tolerance can be induced, but patient safety is adversely affected and treatment cost increases
Solution Approach 1:
The patent uses synthetic microparticles as disposable carriers that can be easily manufactured and discarded after delivering their therapeutic payload. These microparticles carry tolerogenic factors and antigens without requiring expensive ex-vivo cell manipulation, thereby reducing treatment cost while maintaining safety profile
Solution Approach 2:
The microparticles serve as intermediary carriers between the administered tolerogenic factors/antigens and the target dendritic cells. Instead of directly manipulating patient cells ex-vivo, the microparticles mediate the delivery of therapeutic agents to the cells in vivo, eliminating the need for complex ex-vivo cell processing while maintaining therapeutic efficacy
2Reliability
If dendritic cell-based vaccines are used, then tolerance can be promoted, but antigen presentation is inefficient and homing to lymphatic system is poor
Solution Approach 1:
The patent employs dual-sized microparticles with different functions: larger microparticles (50-200 μm) for sustained release of tolerogenic factors at the injection site, and smaller microparticles (0.1-10 μm) for phagocytosis by dendritic cells. This local differentiation of particle sizes optimizes both antigen presentation efficiency and dendritic cell homing to the lymphatic system
Solution Approach 2:
The therapeutic formulation is segmented into two distinct microparticle size classes, each performing a specialized function. The larger particles handle the tolerogenic factor delivery while smaller particles handle antigen presentation and DC recruitment, thereby improving overall system efficiency without compromising tolerance promotion
3Reliability
If non-specific immune-suppressive agents are used, then autoimmune disease can be treated, but off-target actions and side effects increase
Solution Approach 1:
The patent delivers tolerogenic factors and antigens locally at the injection site through microparticles, creating a localized immune modulation effect. This local action minimizes off-target effects compared to systemic immune suppressors, while still achieving effective treatment of autoimmune disease through antigen-specific tolerance induction
Solution Approach 2:
The microparticle system enables the patient's own immune system to treat itself by delivering self-antigens and tolerogenic factors that trigger antigen-specific tolerance. This self-service approach replaces the need for external non-specific immune suppression, eliminating off-target actions while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microparticle system effectively induces antigen-specific immune tolerance, reducing autoimmune responses in multiple sclerosis models by suppressing pathogenic T cells and inflammatory cytokines, achieving robust and durable autoimmune protection with reduced systemic immunosuppression and side effects.
Implementation Method 1
One set of microparticles is phagocytosable by the antigen-presenting immune cell of interest
Implementation Method 2
The non-phagocytosable microparticles together comprise at least one immunosuppressive tolerogenic agent and at least one agent that recruits the antigen-presenting immune cell of interest
Data Source
AI summary
Provided are a dual microparticle system to treat Multiple Sclerosis, the system comprising phagocytosable and non-phagocytosable microparticles for delivery of at least one antigen, at least one immunomodulatory agent, at least one immunosuppressive agent and at least one chemoattractant to a subject suffering from Multiple Sclerosis to generate tolerogenic dendritic cells in the subject and treat the Multiple Sclerosis.